{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:28Z","timestamp":1790223448540,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2015,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30\n                      <jats:sup>+<\/jats:sup>\n                      receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30\n                      <jats:sup>+<\/jats:sup>\n                      cutaneous T-cell lymphomas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Forty-eight patients with CD30\n                      <jats:sup>+<\/jats:sup>\n                      lymphoproliferative disorders or mycosis fungoides (MF) received an infusion of 1.8 mg\/kg every 21 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-eight evaluable patients (22 women and 26 men; median age, 59.5 years) had an overall response rate of 73% (95% CI, 60% to 86%; 35 of 48 patients) and complete response rate of 35% (95% CI, 22% to 49%; 17 of 48 patients). Fifteen (54%; 95% CI, 31% to 59%) of 28 patients with MF responded, independent of CD30 expression. In patients with MF\/S\u00e9zary syndrome, the overall response rate was 50% (five of 10 patients) in patients with low CD30 expression (&lt; 10%), 58% (seven of 12 patients) in patients with medium expression (10% to 50%), and 50% (three of six patients) in patients with high expression (\u2265 50%). Time to response was 12 weeks (range, 3 to 39 weeks), and duration of response was 32 weeks (range, 3 to 93 weeks). All patients with lymphomatoid papulosis (n = 9) and primary cutaneous anaplastic T-cell lymphomas (n = 2) responded; time to response was 3 weeks (range, 3 to 9 weeks), and median duration of response was 26 weeks (range, 6 to 44 weeks). Soluble baseline CD30 levels were lowest in complete responders (P = .036). Grade 1 to 2 peripheral neuropathy was observed in 65% of patients (95% CI, 52% to 79%; 31 of 48 patients), is still ongoing in 55% of patients (95% CI, 41% to 69%; 17 of 31 patients), and resolved in 45% of patients (95% CI, 31% to 59%; 14 of 31 patients), with a median time to resolution of 41.5 weeks. Grade 3 to 4 events were neutropenia (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and dehydration (n = 1). Dose reductions to 1.2 mg\/kg were instituted as a result of grade 2 neuropathy (n = 6), transaminitis (n = 1), and arthralgias and fatigue (n = 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an overall response rate of 73% and complete response rate of 35%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2014.60.3787","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T22:39:18Z","timestamp":1439246358000},"page":"3759-3765","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":281,"title":["Results of a Phase II Trial of Brentuximab Vedotin for CD30\n                    <sup>+<\/sup>\n                    Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis"],"prefix":"10.1200","volume":"33","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Gangar","sequence":"additional","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra L.","family":"Clos","sequence":"additional","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawen","family":"Sui","sequence":"additional","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshandra","family":"Talpur","sequence":"additional","affiliation":[{"name":"All authors: The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen E","year":"2007","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830190125"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0290"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110608"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-011-0096-8"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)00138-0"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351346"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700122"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03711.x"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03024.x"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0033"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03771.x"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1150"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-154609"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0162"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.9.3369"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403202"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"B27","first-page":"17","volume":"2","author":"Rangwala S","year":"2012","journal-title":"Blood Lymphatic Cancer Target Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.017"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2014.60.3787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:05:56Z","timestamp":1653509156000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2014.60.3787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,10]]},"references-count":28,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015,11,10]]}},"alternative-id":["10.1200\/JCO.2014.60.3787"],"URL":"https:\/\/doi.org\/10.1200\/jco.2014.60.3787","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,10]]},"assertion":[{"value":"2015-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}